| scholarly article | Q13442814 |
| P50 | author | Elaine Mardis | Q5353251 |
| Kilannin Krysiak | Q47502229 | ||
| Timothy A. Graubert | Q55130327 | ||
| Michael H Tomasson | Q59542415 | ||
| Michael D McLellan | Q59542438 | ||
| Jack Baty | Q117256852 | ||
| Joelle Kalicki-Veizer | Q125341223 | ||
| Marcus Grillot | Q125342268 | ||
| P2093 | author name string | Christopher C Harris | |
| Li Ding | |||
| Richard K Wilson | |||
| Talat Nasim | |||
| Robert S Fulton | |||
| Daniel C Koboldt | |||
| Jin Shao | |||
| David J Dooling | |||
| Dong Shen | |||
| Timothy J Ley | |||
| David E Larson | |||
| Heather Schmidt | |||
| John F DiPersio | |||
| John L Frater | |||
| Matthew J Walter | |||
| Daniel C Link | |||
| Peter Westervelt | |||
| Sharon Heath | |||
| Michelle O'Laughlin | |||
| Rachel M Abbott | |||
| Theresa Okeyo-Owuor | |||
| Cara L Lunn | |||
| P2860 | cites work | A novel peptide recognition mode revealed by the X-ray structure of a core U2AF35/U2AF65 heterodimer | Q24291672 |
| Interactions of CCCH zinc finger proteins with mRNA: non-binding tristetraprolin mutants exert an inhibitory effect on degradation of AU-rich element-containing mRNAs | Q24292131 | ||
| Identification of RPS14 as a 5q- syndrome gene by RNA interference screen | Q24306795 | ||
| In vivo requirement of the small subunit of U2AF for recognition of a weak 3' splice site | Q39125810 | ||
| A double-reporter splicing assay for determining splicing efficiency in mammalian cells | Q40150084 | ||
| Functional recognition of the 3' splice site AG by the splicing factor U2AF35. | Q40908643 | ||
| The emerging role of splicing factors in cancer | Q43244074 | ||
| Insertional mutagenesis in zebrafish rapidly identifies genes essential for early vertebrate development | Q44638792 | ||
| Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. | Q47956567 | ||
| An inequality with applications to statistical estimation for probabilistic functions of Markov processes and to a model for ecology | Q56115033 | ||
| SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts | Q84876020 | ||
| Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 | ||
| Significance analysis of microarrays applied to the ionizing radiation response | Q24606608 | ||
| Recurring mutations found by sequencing an acute myeloid leukemia genome | Q24634204 | ||
| DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome | Q24644436 | ||
| Fast and accurate short read alignment with Burrows-Wheeler transform | Q24653853 | ||
| DAVID: Database for Annotation, Visualization, and Integrated Discovery | Q27499374 | ||
| DNMT3A Mutations in Acute Myeloid Leukemia | Q27559610 | ||
| Recognition of the mRNA AU-rich element by the zinc finger domain of TIS11d | Q27643189 | ||
| Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes | Q27851571 | ||
| Recurrent DNMT3A mutations in patients with myelodysplastic syndromes | Q27851629 | ||
| Use of whole-genome sequencing to diagnose a cryptic fusion oncogene | Q27851641 | ||
| Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts | Q27851675 | ||
| The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data | Q27860742 | ||
| A method and server for predicting damaging missense mutations | Q27860835 | ||
| The Sequence Alignment/Map format and SAMtools | Q27860966 | ||
| The spliceosome: design principles of a dynamic RNP machine | Q28131809 | ||
| Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged | Q28297381 | ||
| Genome remodelling in a basal-like breast cancer metastasis and xenograft | Q28395637 | ||
| SIFT: Predicting amino acid changes that affect protein function | Q29547211 | ||
| Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders | Q29614510 | ||
| Frequent pathway mutations of splicing machinery in myelodysplasia | Q29616088 | ||
| Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads | Q29617402 | ||
| Mutation in TET2 in myeloid cancers | Q29619292 | ||
| Genome-wide survey and expression profiling of CCCH-zinc finger family reveals a functional module in macrophage activation | Q33358022 | ||
| Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis | Q33412120 | ||
| VarScan: variant detection in massively parallel sequencing of individual and pooled samples | Q34018143 | ||
| Allele-specific recognition of the 3' splice site of INS intron 1 | Q34127329 | ||
| U2AF35 is encoded by an essential gene clustered in an operon with RRM/cyclophilin in Caenorhabditis elegans | Q34361829 | ||
| Acquired mutations in TET2 are common in myelodysplastic syndromes | Q34984094 | ||
| BreakDancer: an algorithm for high-resolution mapping of genomic structural variation | Q34996567 | ||
| AG-dependent 3'-splice sites are predisposed to aberrant splicing due to a mutation at the first nucleotide of an exon. | Q35017903 | ||
| RNA interference knockdown of hU2AF35 impairs cell cycle progression and modulates alternative splicing of Cdc25 transcripts | Q35128178 | ||
| Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. | Q35205646 | ||
| Mutations in the small subunit of the Drosophila U2AF splicing factor cause lethality and developmental defects | Q37337043 | ||
| The splicing factor U2AF small subunit is functionally conserved between fission yeast and humans | Q37732601 | ||
| POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature | Q38345022 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 53-57 | |
| P577 | publication date | 2011-12-11 | |
| P1433 | published in | Nature Genetics | Q976454 |
| P1476 | title | Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes | |
| P478 | volume | 44 |
| Q35690609 | A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets |
| Q39787266 | A network-based analysis of colon cancer splicing changes reveals a tumorigenesis-favoring regulatory pathway emanating from ELK1 |
| Q40228044 | A preliminary study on the outcome of lower-risk myelodysplastic syndrome by low-dose decitabine |
| Q99631221 | Aberrant RNA Splicing in Cancer |
| Q34047994 | Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukemia |
| Q34044691 | Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes |
| Q58759797 | Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia |
| Q57793811 | Aberrant splicing in B-cell acute lymphoblastic leukemia |
| Q35148150 | Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome |
| Q38139915 | Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors |
| Q36849666 | Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification |
| Q37593486 | Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2. |
| Q90700699 | Altered RNA Processing in Cancer Pathogenesis and Therapy |
| Q92297076 | Alternative mRNA splicing in cancer immunotherapy |
| Q34418393 | An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth |
| Q47220965 | Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. |
| Q36050710 | BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients |
| Q38278197 | CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q). |
| Q38929862 | CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis. |
| Q22242276 | Cancer genome landscapes |
| Q34301519 | Cancer genomics and pathology: all together now. |
| Q47889480 | Cancer-Associated Mutations Mapped on High-Resolution Structures of the U2AF2 RNA Recognition Motifs |
| Q37643870 | Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures |
| Q27683637 | Cancer-relevant Splicing Factor CAPERα Engages the Essential Splicing Factor SF3b155 in a Specific Ternary Complex |
| Q36998431 | Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics |
| Q38905610 | Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome |
| Q37334716 | Clinical and biological implications of driver mutations in myelodysplastic syndromes |
| Q48149987 | Clinical features and biological implications of different U2AF1 mutation types in myelodysplastic syndromes |
| Q27852437 | Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression. |
| Q94484010 | Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia |
| Q41240561 | Clinical significance of somatic mutation in unexplained blood cytopenia |
| Q92802700 | Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome |
| Q35872658 | Clonal architecture of secondary acute myeloid leukemia |
| Q37078001 | Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. |
| Q98205261 | Complex landscape of alternative splicing in myeloid neoplasms |
| Q57261157 | Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients |
| Q26865671 | Connections between TET proteins and aberrant DNA modification in cancer |
| Q97067692 | Contribution of Aberrant Toll Like Receptor Signaling to the Pathogenesis of Myelodysplastic Syndromes |
| Q37139543 | Ddx46 is required for multi-lineage differentiation of hematopoietic stem cells in zebrafish |
| Q37742267 | Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone |
| Q34311583 | Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria. |
| Q28077564 | Defective control of pre-messenger RNA splicing in human disease |
| Q26823040 | Defects in spliceosomal machinery: a new pathway of leukaemogenesis |
| Q36407860 | Detection of alternative splicing during epithelial-mesenchymal transition |
| Q37999070 | Detection of copy number alterations in acute myeloid leukemia and myelodysplastic syndromes |
| Q37263146 | Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet |
| Q89267526 | Diagnostic algorithm for lower-risk myelodysplastic syndromes |
| Q101121109 | Differential U2AF1 mutation sites, burden and co-mutation genes can predict prognosis in patients with myelodysplastic syndrome |
| Q37309196 | Discovering transcription and splicing networks in myelodysplastic syndromes |
| Q52313265 | Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs. |
| Q41657181 | Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators |
| Q92267361 | Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: A meta-analysis |
| Q99594522 | Elucidation of the aberrant 3' splice site selection by cancer-associated mutations on the U2AF1 |
| Q92081372 | Emerging Therapeutic Opportunities Based on Current Knowledge of Uveal Melanoma Biology |
| Q28074522 | Emerging concepts of epigenetic dysregulation in hematological malignancies |
| Q38071747 | Emerging importance of mutational analysis in myelodysplastic syndrome and acute myelogenous leukemia |
| Q27014126 | Emerging patterns of somatic mutations in cancer |
| Q38017093 | Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders |
| Q36737884 | Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy |
| Q26828777 | Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they? |
| Q35713371 | Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia. |
| Q26991754 | Evolutionary conservation and expression of human RNA-binding proteins and their role in human genetic disease |
| Q41296537 | Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia |
| Q37654921 | Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes |
| Q48385629 | Extensive cryptic splicing upon loss of RBM17 and TDP43 in neurodegeneration models |
| Q91583393 | FBXO22 degrades nuclear PTEN to promote tumorigenesis |
| Q33810850 | Follicle-stimulating hormone receptor (FSHR) alternative skipping of exon 2 or 3 affects ovarian response to FSH |
| Q43428613 | Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. |
| Q26827640 | From human genome to cancer genome: the first decade |
| Q36422245 | Functional impact bias reveals cancer drivers |
| Q91972757 | Functional significance of U2AF1 S34F mutations in lung adenocarcinomas |
| Q34640898 | Functional study of one nucleotide mutation in pri-miR-125a coding region which related to recurrent pregnancy loss |
| Q36296996 | Functions of Replication Protein A as a Sensor of R Loops and a Regulator of RNaseH1 |
| Q92541091 | Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia |
| Q49817248 | Gene mutations from 511 myelodysplastic syndromes patients performed by targeted gene sequencing |
| Q35995222 | Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome |
| Q90245162 | Genetic basis of myelodysplastic syndromes |
| Q40385815 | Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes. |
| Q57180196 | Genomic Characteristics of Myeloproliferative Neoplasms in Patients Exposed to Ionizing Radiation following the Chernobyl Nuclear Accident |
| Q37662261 | Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations |
| Q33767762 | Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers. |
| Q38182932 | Genomic tools in acute myeloid leukemia: From the bench to the bedside |
| Q38016170 | Genomics of acute myeloid leukemia: the next generation |
| Q43820064 | Haploinsufficiency of Sf3b1 leads to compromised stem cell function but not to myelodysplasia |
| Q53518700 | High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS). |
| Q33640195 | How do messenger RNA splicing alterations drive myelodysplasia? |
| Q38265600 | How mRNA is misspliced in acute myelogenous leukemia (AML)? |
| Q38235622 | I walk the line: how to tell MDS from other bone marrow failure conditions |
| Q38830136 | Identification and analysis of mutational hotspots in oncogenes and tumour suppressors. |
| Q101409894 | Identification of phenothiazine derivatives as UHM-binding inhibitors of early spliceosome assembly |
| Q40957638 | Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations |
| Q38600683 | Impact of genetic variants on haematopoiesis in patients with thrombocytopenia absent radii (TAR) syndrome |
| Q57797263 | Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes |
| Q57465846 | Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene |
| Q47130430 | Implications of mutational spectrum in myelodysplastic syndromes based on targeted next-generation sequencing |
| Q38826127 | Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy |
| Q50057508 | Insights from structures of cancer-relevant pre-mRNA splicing factors |
| Q38218055 | Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution |
| Q89507900 | Integrative Profiling of Alternative Splicing Induced by U2AF1 S34F Mutation in Lung Adenocarcinoma Reveals a Mechanistic Link to Mitotic Stress |
| Q92999641 | Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer |
| Q34411315 | Kinetic competition during the transcription cycle results in stochastic RNA processing |
| Q38755963 | Knockdown of USP39 induces cell cycle arrest and apoptosis in melanoma |
| Q42335811 | Lack of splice factor and cohesin complex mutations in pediatric myelodysplastic syndrome |
| Q37571585 | Landscape of genetic lesions in 944 patients with myelodysplastic syndromes |
| Q38123015 | Lessons from next-generation sequencing analysis in hematological malignancies. |
| Q38099307 | Leveraging cancer genome information in hematologic malignancies |
| Q46191604 | Long noncoding RNAs in hematopoietic malignancies |
| Q39157705 | Loss of p300 accelerates MDS-associated leukemogenesis |
| Q37545704 | Loss of the tumor suppressor BAP1 causes myeloid transformation |
| Q28275103 | Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing |
| Q39483070 | Mixed Mesonephric Adenocarcinoma and High-grade Neuroendocrine Carcinoma of the Uterine Cervix: Case Description of a Previously Unreported Entity With Insights Into Its Molecular Pathogenesis |
| Q47108992 | Modeling Myeloid Malignancies Using Zebrafish. |
| Q36984373 | Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins |
| Q90250949 | Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis |
| Q26749870 | Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy |
| Q40817471 | Molecular basis of myelodysplastic syndromes |
| Q38248429 | Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable. |
| Q37724602 | Molecular pathogenesis of myelodysplastic syndromes |
| Q38451022 | Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment |
| Q36445968 | Molecular pathophysiology of myelodysplastic syndromes. |
| Q35604082 | Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo |
| Q37581442 | Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome |
| Q40902348 | Mutated genes and driver pathways involved in myelodysplastic syndromes—a transcriptome sequencing based approach |
| Q45383525 | Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors |
| Q47663665 | Mutational landscape of RNA-binding proteins in human cancers |
| Q92114066 | Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies |
| Q35876928 | Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis |
| Q86194930 | Myelodysplasia: new approaches |
| Q64108132 | Myelodysplastic Syndrome-Associated SRSF2 Mutations Cause Splicing Changes by Altering Binding Motif Sequences |
| Q38050694 | Myelodysplastic syndrome hematopoietic stem cell |
| Q38203323 | Myelodysplastic syndromes in the United States: an update for clinicians |
| Q36416338 | Myelodysplastic syndromes, version 2.2015 |
| Q27000577 | Myeloid malignancies: mutations, models and management |
| Q39576319 | Myelopoiesis and myeloid leukaemogenesis in the zebrafish |
| Q33556923 | NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML |
| Q42157464 | Natural history of chronic myelomonocytic leukemia: gene sequencing identifies multiple clonal molecular abnormalities associated with rapid progression to acute myeloid leukemia |
| Q27853094 | Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations |
| Q38036607 | Next-generation sequencing reveals the secrets of the chronic lymphocytic leukemia genome. |
| Q38453790 | Next-generation sequencing-based panel testing for myeloid neoplasms |
| Q38716306 | Novel therapeutic strategies in myelodysplastic syndromes: do molecular genetics help? |
| Q55212155 | Nuclear PTEN safeguards pre-mRNA splicing to link Golgi apparatus for its tumor suppressive role. |
| Q37076932 | Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome |
| Q37559783 | Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD). |
| Q34667249 | Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease |
| Q37083971 | Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms |
| Q35822289 | Pharmacodynamic assays to facilitate preclinical and clinical development of pre-mRNA splicing modulatory drug candidates |
| Q38286217 | Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance |
| Q38028093 | Pre-mRNA splicing in disease and therapeutics |
| Q53246202 | Preferential occurrence of spliceosome mutations in acute myeloid leukemia with preceding myelodysplastic syndrome and/or myelodysplasia morphology. |
| Q37683379 | Preleukemia: one name, many meanings |
| Q95334402 | RNA Splicing and Cancer |
| Q92755595 | RNA components of the spliceosome regulate tissue- and cancer-specific alternative splicing |
| Q100750569 | RNA in cancer |
| Q37391660 | RNA splicing factors as oncoproteins and tumour suppressors |
| Q92985388 | RNA-binding proteins in hematopoiesis and hematological malignancy |
| Q92802674 | Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations |
| Q35538419 | Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies |
| Q94536489 | Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches |
| Q39096716 | Recent advances in understanding clonal haematopoiesis in aplastic anaemia |
| Q38122703 | Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes |
| Q48730157 | Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes |
| Q56969038 | Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita |
| Q90433841 | Regulating Divergent Transcriptomes through mRNA Splicing and Its Modulation Using Various Small Compounds |
| Q58711347 | Role of alternative splicing in hematopoietic stem cells during development |
| Q34348631 | Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. |
| Q92025312 | Roles and mechanisms of alternative splicing in cancer - implications for care |
| Q89919982 | Roles of Splicing Factors in Hormone-Related Cancer Progression |
| Q35849733 | SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS. |
| Q38779660 | SF1 Phosphorylation Enhances Specific Binding to U2AF65 and Reduces Binding to 3'-Splice-Site RNA. |
| Q42583765 | SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype |
| Q27852162 | SF3B1 mutations in chronic lymphocytic leukemia |
| Q35917455 | SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing |
| Q35601110 | SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition |
| Q92702822 | SRSF2 Mutations in Uveal Melanoma: A Preference for In-Frame Deletions? |
| Q36579076 | Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics |
| Q37133403 | Short telomere length and its correlation with gene mutations in myelodysplastic syndrome |
| Q53087647 | Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance. |
| Q37060418 | Somatic SETBP1 mutations in myeloid malignancies |
| Q37688233 | Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome |
| Q34396189 | Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation |
| Q38289057 | Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy |
| Q36498395 | Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia |
| Q26752221 | Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis |
| Q90579483 | Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes |
| Q38000919 | Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies. |
| Q36967122 | Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome |
| Q83140566 | Spliceosome mutations in hematopoietic malignancies |
| Q38074757 | Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia. |
| Q39217354 | Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures |
| Q39035441 | Splicing factor gene mutations in hematologic malignancies |
| Q38187632 | Splicing factor mutations and cancer |
| Q38051189 | Splicing factor mutations in myelodysplasia |
| Q38684557 | Splicing in immune cells-mechanistic insights and emerging topics |
| Q38929098 | Splicing-factor alterations in cancers |
| Q38157706 | Standardizing the initial evaluation for myelodysplastic syndromes |
| Q89847527 | Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity |
| Q34047259 | Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms. |
| Q38059391 | The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics |
| Q38214084 | The Importance of Multidisciplinary Approach in Early Detection of BAP1 Tumor Predisposition Syndrome: Clinical Management and Risk Assessment |
| Q46478352 | The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype |
| Q33746465 | The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes |
| Q47820600 | The cancer-associated U2AF35 470A>G (Q157R) mutation creates an in-frame alternative 5' splice site that impacts splicing regulation in Q157R patients |
| Q90159661 | The core spliceosomal factor U2AF1 controls cell-fate determination via the modulation of transcriptional networks |
| Q38033985 | The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. |
| Q91045747 | The functional mechanisms of mutations in myelodysplastic syndrome |
| Q37390236 | The genetic basis of myelodysplasia and its clinical relevance |
| Q38061848 | The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes |
| Q33796552 | The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia |
| Q47099740 | The genomic landscape of pediatric myelodysplastic syndromes. |
| Q38341998 | The molecular pathogenesis of the myelodysplastic syndromes |
| Q38245878 | The myelodysplastic syndromes: the era of understanding |
| Q35675958 | The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts |
| Q39253959 | The role of RNA alternative splicing in regulating cancer metabolism. |
| Q28083838 | The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression |
| Q38057608 | The spliceosome as a target of novel antitumour drugs |
| Q34492012 | The spliceosome is a therapeutic vulnerability in MYC-driven cancer |
| Q24302434 | The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers |
| Q63649310 | The splicing factor U2AF1 contributes to cancer progression through a noncanonical role in translation regulation |
| Q37224370 | The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts |
| Q89962571 | The zinc finger domains in U2AF26 and U2AF35 have diverse functionalities including a role in controlling translation |
| Q38948363 | Therapeutic targeting of splicing in cancer |
| Q94673038 | Transcriptome profiling reveals the high incidence of hnRNPA1 exon 8 inclusion in chronic myeloid leukemia |
| Q37600407 | Transplantation for myelodysplastic syndromes 2013. |
| Q35348356 | U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing |
| Q42088141 | U2AF1 mutations alter splice site recognition in hematological malignancies |
| Q27851921 | U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome |
| Q45961967 | U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. |
| Q90215311 | U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies |
| Q38770604 | U2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 Pre-mRNA 3' End Formation. |
| Q104795203 | U2af1 is required for survival and function of hematopoietic stem/progenitor cells |
| Q36222935 | Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes |
| Q34213994 | What are we learning from the cancer genome? |
| Q58570841 | Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer |
| Q40794680 | Widespread intron retention diversifies most cancer transcriptomes |
| Q36173000 | Wild-Type U2AF1 Antagonizes the Splicing Program Characteristic of U2AF1-Mutant Tumors and Is Required for Cell Survival |
| Q89550333 | [Clinical features and prognostic analysis of myelodysplastic syndromes patients with U2AF1 mutation] |
| Q88739459 | [High throughput sequencing combined with DNA-PCR for detection of 51 kinds of hematologic malignancy related gene mutations in patients with myelodysplastic syndromes] |
| Q87798191 | [Mutational analysis of RNA splicing machinery genes SF3B1, U2AF1 and SRSF2 in 118 patients with myelodysplastic syndromes and related diseases] |
| Q89319295 | [U2AF1 mutations in 349 patients with myelodysplastic syndrome] |
Search more.